Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.

Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T.

J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):349-53. doi: 10.1176/appi.neuropsych.11110325.

PMID:
23037649
2.

Duloxetine versus other anti-depressive agents for depression.

Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. doi: 10.1002/14651858.CD006533.pub2. Review.

3.
4.

Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.

Bose A, Tsai J, Li D.

Clin Drug Investig. 2012 Jun 1;32(6):373-85. doi: 10.2165/11631890-000000000-00000.

PMID:
22559255
5.

An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.

Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M.

J Clin Psychopharmacol. 2005 Dec;25(6):552-60.

PMID:
16282837
6.

Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.

Bould H, Wiles N, Potokar J, Cowen P, Nutt DJ, Peters TJ, Lewis G.

J Psychopharmacol. 2012 May;26(5):663-9. doi: 10.1177/0269881111431753. Epub 2012 Jan 4.

PMID:
22223618
7.

Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.

Solaro C, Bergamaschi R, Rezzani C, Mueller M, Trabucco E, Bargiggia V, Dematteis F, Mattioda A, Cimino V, Restivo D, Patti F, Cavalla P.

Clin Neuropharmacol. 2013 Jul-Aug;36(4):114-6. doi: 10.1097/WNF.0b013e3182996400.

PMID:
23783007
8.

Early symptom change prediction of remission in depression treatment.

Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP.

Psychopharmacol Bull. 2009;42(1):94-107.

PMID:
19204654
9.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
10.

Duloxetine in treatment of anxiety symptoms associated with depression.

Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.

Depress Anxiety. 2003;18(2):53-61.

PMID:
12964171
11.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
12.

Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.

Andersen G, Vestergaard K, Lauritzen L.

Stroke. 1994 Jun;25(6):1099-104.

PMID:
8202964
13.

Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.

Mullins CD, Shaya FT, Meng F, Wang J, Harrison D.

Pharmacotherapy. 2005 May;25(5):660-7.

PMID:
15899727
14.

Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.

Wohlreich MM, Mallinckrodt CH, Watkin JG, Wilson MG, Greist JH, Delgado PL, Fava M.

Ann Clin Psychiatry. 2005 Oct-Dec;17(4):259-68.

PMID:
16402760
15.

Antidepressant therapy in post-stroke depression.

Starkstein SE, Mizrahi R, Power BD.

Expert Opin Pharmacother. 2008 Jun;9(8):1291-8. doi: 10.1517/14656566.9.8.1291 . Review.

PMID:
18473704
16.

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.

Clin Drug Investig. 2007;27(7):481-92.

PMID:
17563128
17.

[Impact of duloxetine on depression and anxiety in patients with ankylosing spondylitis: a case-control study].

Li Y, Zhang SL, Zhu J, DU XN, Huang ZF, Huang F.

Zhonghua Yi Xue Za Zhi. 2013 Apr 2;93(13):966-9. Chinese.

PMID:
23886255
18.
19.

Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.

Llorca PM, Lançon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C.

Curr Med Res Opin. 2014 Dec;30(12):2589-606. doi: 10.1185/03007995.2014.969566. Epub 2014 Oct 10.

PMID:
25249164
20.

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.

Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ; Zoloft's Effects on Symptoms and survival Time Trial Group.

Lancet Oncol. 2007 Jul;8(7):603-12. Erratum in: Lancet Oncol. 2007 Jul 8;8(7):574.

PMID:
17548243
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk